Registration Dossier
Registration Dossier
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 449-400-0 | CAS number: 25822-43-9
Endpoint summary
Administrative data
Description of key information
The test item was tested for acute oral toxicity according to OECD 423. The LD50 was estimated to be > 2000 mg/kg bw in male and female rats.
The test item was tested for acute dermal toxicity according to OECD 402. The LD50 was estimated to be > 2000 mg/kg bw in male and female rats.
Key value for chemical safety assessment
Acute toxicity: via oral route
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed
- Dose descriptor:
- discriminating dose
- Value:
- 2 000 mg/kg bw
- Quality of whole database:
- GLP and guideline compliant study.
Acute toxicity: via inhalation route
Endpoint conclusion
- Endpoint conclusion:
- no study available
Acute toxicity: via dermal route
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed
- Dose descriptor:
- discriminating dose
- Value:
- 2 000 mg/kg bw
- Quality of whole database:
- GLP and guideline compliant study.
Additional information
Acute oral toxicity
The aim of the study was to investigate acute toxic effects of the test item after a single peroral administration to Sprague-Dawley rats according to the OECD 423. Administration of 200 and 2000 mg/kg bw were performed once per gavage to 3 males and 3 females, respectively. No clinical signs of toxicity and no mortality were observed within the observation period of 14 days. The LD50 was estimated to be > 2000 mg/kg bw.
Acute dermal toxicity
The aim of the study was to investigate acute toxic effects of the test item after a single dermal administration to rats according to the OECD 402. Administration of 2000 mg/kg bw were performed once under semi-occlusive conditions to 5 males and 5 females, respectively. No mortality and no signs of clinical toxicity were observed within the observation period of 14 days. The LD50 was estimated to be > 2000 mg/kg bw.
Acute inhalation toxicity
There is no study available for acute inhalation toxicity.
Justification for selection of acute toxicity – oral endpoint
GLP and guideline compliant
Justification for selection of acute toxicity – dermal endpoint
GLP and guideline compliant study.
Justification for classification or non-classification
No mortality and no toxic effects of the test item were observed during the study period. The test item is therefore classified as "not acute toxic" after oral application according to the Directive 67/548/EEC (DSD) and the Regulation (EC) No 1272/2008 (CLP).
No mortality and no toxic effects of the test item were observed during the study period. The test item is therefore classified as "not acute toxic" after oral application according to the Directive 67/548/EEC (DSD) and the Regulation (EC) No 1272/2008 (CLP).
There is no study available for acute inhalation toxicity.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
